RT Journal Article
SR Electronic
T1 COVID-19 pandemic in the African continent: Forecasts of cumulative cases, new infections, and mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.09.20059154
DO 10.1101/2020.04.09.20059154
A1 Achoki, T
A1 Alam, U
A1 Were, L
A1 Gebremedhin, T
A1 Senkubuge, F
A1 Lesego, A
A1 Liu, S
A1 Wamai, R
A1 Kinfu, Y
YR 2020
UL http://medrxiv.org/content/early/2020/04/28/2020.04.09.20059154.abstract
AB Background The epidemiology of COVID-19 remains speculative in Africa. To the best of our knowledge, no study, using robust methodology provides its trajectory for the region or accounts for local context. This paper is the first systematic attempt to provide prevalence, incidence, and mortality estimates across Africa.Methods Caseloads and incidence forecasts are from a co-variate-based instrumental variable regression model. Fatality rates from Italy and China were applied to generate mortality estimates after making relevant health system and population-level characteristics related adjustments between each of the African countries.Results By June 30 2020, around 16.3 million people in Africa will contract COVID-19 (95% CI 718,403 to 98,358,799). Northern and Eastern Africa will be the most and least affected areas. Cumulative cases by June 30 are expected to reach around 2.9 million (95% CI 465,028 to 18,286,358) in Southern Africa, 2.8 million (95% CI 517,489 to 15,056,314) in Western Africa, and 1.2 million (95% CI 229,111 to 6,138,692) in Central Africa. Incidence for the month of April 2020 is expected to be highest in Djibouti, 32.8 per 1000 (95% CI 6.25 to 171.77), while Morocco will experience among the highest fatalities (1,045 deaths, 95% CI 167 to 6,547).Conclusion Less urbanized countries with low levels of socio-economic development (hence least connected to the world), are likely to register lower and slower transmissions at the early stages of an epidemic. However, the same enabling factors that worked for their benefit can hinder interventions that have lessened the impact of COVID-19 elsewhere.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo direct funding was solicited for the studyAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publically available http://ghdx.healthdata.org/ https://www.prb.org/data/ https://www.un.org https://coronavirus.jhu.edu/data https://www.who.int/healthinfo/statistics/en/